Know Cancer

or
forgot password


N/A
N/A
21 Years
Not Enrolling
Both
Pediatric Inflammatory Bowel Disease

Thank you

Trial Information


Inclusion Criteria:



- All individuals who received at least 2 doses of infliximab before the age of 16 at
the pediatric IBD Center at Cedars Sinai Medical Center for the treatment of Crohn's
disease or ulcerative colitis Able to give consent

Exclusion Criteria:

- not exposed to infliximab

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Frequency of patients with a sustained durable remision and frequency of serious infections and malignancies in children exposed to infliximab

Outcome Time Frame:

10 years

Safety Issue:

Yes

Principal Investigator

Marla Dubinsky

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cedar Sinai Medical Center

Authority:

United States: Institutional Review Board

Study ID:

REMICADEIBD4008

NCT ID:

NCT01490528

Start Date:

January 2012

Completion Date:

Related Keywords:

  • Pediatric Inflammatory Bowel Disease
  • Pediatric IBD
  • Inflammatory Bowel Diseases
  • Intestinal Diseases

Name

Location